COG vs. RENX, INHC, FDBK, IQAI, TRLS, DVRG, SENS, EMIS, CRW, and INS
Should you be buying Cambridge Cognition stock or one of its competitors? The main competitors of Cambridge Cognition include Renalytix (RENX), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), Trellus Health (TRLS), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.
Cambridge Cognition (LON:COG) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Renalytix has a net margin of 0.00% compared to Cambridge Cognition's net margin of -10.07%. Cambridge Cognition's return on equity of -74.36% beat Renalytix's return on equity.
Cambridge Cognition has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500.
In the previous week, Cambridge Cognition had 5 more articles in the media than Renalytix. MarketBeat recorded 5 mentions for Cambridge Cognition and 0 mentions for Renalytix. Cambridge Cognition's average media sentiment score of 0.32 beat Renalytix's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the media.
Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
37.7% of Cambridge Cognition shares are owned by institutional investors. Comparatively, 28.4% of Renalytix shares are owned by institutional investors. 29.9% of Cambridge Cognition shares are owned by insiders. Comparatively, 35.8% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cambridge Cognition received 82 more outperform votes than Renalytix when rated by MarketBeat users. However, 74.19% of users gave Renalytix an outperform vote while only 44.30% of users gave Cambridge Cognition an outperform vote.
Summary
Cambridge Cognition beats Renalytix on 9 of the 15 factors compared between the two stocks.
Get Cambridge Cognition News Delivered to You Automatically
Sign up to receive the latest news and ratings for COG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cambridge Cognition Competitors List
Related Companies and Tools
Free COG Stock Alerts